Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback